Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) is a leading cause of morbidity in diabetes mellitus, primarily resulting from persistent hyperglycemia, oxidative stress, and lipid peroxidation–induced renal injury. Natural phytoconstituents with potent antioxidant and insulin-sensitizing properties offer promise in mitigating such complications. This study investigated the combined nephroprotective efficacy of HBAO (2β-hydroxybetulinic acid 3β-oleiate) isolated from Euryale ferox and ALD-1 (7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one) isolated from Albizzia lebbeck Benth. in streptozotocin (STZ)-induced diabetic rats exhibiting features of CKD.
Male Wistar rats were divided into six groups (n = 8): normal control, diabetic control, HBAO (60 mg/kg), ALD-1 (60 mg/kg), combination (HBAO + ALD-1, each 40 mg/kg), and metformin (100 mg/kg). Treatments were administered orally for 45 days. Blood glucose, plasma insulin, glycosylated hemoglobin (HbA1c), renal function markers (serum creatinine, urea, BUN), lipid profile, and antioxidant enzymes (SOD, CAT, GPx) were measured. Renal histopathology was examined to assess structural protection.
STZ-induced diabetic rats developed significant (p < 0.001) hyperglycemia (341 ± 14 mg/dL), elevated HbA1c (9.2 ± 0.4 %), increased serum creatinine (1.8 ± 0.1 mg/dL), and urea (62 ± 3 mg/dL), along with decreased insulin (7.8 ± 0.5 µIU/mL) and antioxidant enzymes. Treatment with HBAO or ALD-1 alone ameliorated these alterations; however, their combination exhibited a synergistic effect, lowering blood glucose to 142 ± 9 mg/dL, HbA1c to 6.1 ± 0.3 %, and serum creatinine and urea to 0.9 ± 0.05 mg/dL and 34 ± 2 mg/dL, respectively. Antioxidant enzymes SOD, CAT, and GPx increased significantly (p < 0.01) toward normal levels. Histopathological evaluation showed marked restoration of glomerular and tubular morphology, with minimal basement membrane thickening and absence of hyaline deposition, comparable to metformin treatment.
The combination of HBAO and ALD-1 demonstrates potent antidiabetic, antioxidant, and nephroprotective activities, effectively preventing the progression of diabetic chronic kidney disease. Their synergistic action, mediated through oxidative stress reduction and renal functional restoration, highlights a promising phytotherapeutic approach for managing diabetic nephropathy and CKD.
